Pricing Log in Create free account

Burning Rock Biotech Limited Sponsored ADR (BNR) vs Exagen Inc. (XGN)

Burning Rock Biotech Limited Sponsored ADR and Exagen Inc. are both Diagnostics & Research companies. Exagen Inc. is the larger, with a market value of $207.4M against $137.1M — 1.5× the size. Exagen Inc. grew revenue faster over the last twelve months: 20.8% against −0.14%. Burning Rock Biotech Limited Sponsored ADR has the higher net margin (−13.5% vs −26.6%) and the higher return on invested capital (−50.7% vs −68.3%). Across the 18 metrics below, Burning Rock Biotech Limited Sponsored ADR leads on 11 and Exagen Inc. on 7.

Valuation

Metric BNR XGN Diagnostics & Research median
P/E n/m n/m 35.56
P/S 18.73 2.60 4.37
P/B 18.81 15.13 3.06
Price to free cash flow n/m n/m 35.76
EV/EBITDA n/m n/m 24.35
EV/Sales 17.89 2.60 5.51
Earnings yield (4.09%) (10.59%) (1.89%)
Free cash flow yield (1.06%) (4.10%) (0.15%)

Profitability

Metric BNR XGN Diagnostics & Research median
Gross margin 74.50% 58.64% 50.89%
Operating margin (12.95%) (18.58%) (8.57%)
Net margin (13.51%) (26.61%) (6.37%)
Free cash flow margin (3.00%) (10.66%) 0.00%
Return on equity (13.08%) (113.82%) (2.92%)
Return on assets (8.81%) (34.19%) (6.71%)
Return on invested capital (50.66%) (68.33%) 0.00%

Growth

Metric BNR XGN Diagnostics & Research median
Revenue growth (TTM) (0.14%) 20.83% 7.69%
EPS growth (last fiscal year) 84.16% (12.05%) 25.92%
Revenue growth, 5-year CAGR 3.21% 9.66% 7.40%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric BNR XGN Diagnostics & Research median
Debt to equity 0.00 2.00 0.11
Current ratio 3.05 3.18 2.02
Net debt to EBITDA 14.48 0.68 0.70

Dividend

Metric BNR XGN Diagnostics & Research median
Dividend yield — — 0.66%
Payout ratio — — 0.20

Size

Metric BNR XGN Diagnostics & Research median
Market cap 137.12m 207.37m 2.16b

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack